Astellas Pharma Gmbh

Kohei Inamura

Shinobu Mochizuki

Yorikata Sano

Hiromichi Yokoi

Takeyuki Nagashima

Kenichi Kawaguchi

Eiji Kawaminami

Sunao Imada

Hisao Hamaguchi

Kazuyuki Kuramoto

Tomoyoshi Imaizumi

Mitsuaki Okumura

Hideyuki Watanabe

Katsura Nozawa

Hiroki Ishioka

Tomohiro Yoshinari

[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.

Quinazoline compound for inducing degradation of G12D mutant KRAS protein

A screening tool and a screening method of a substance which is useful as an agent for improving the memory, an agent for improving learning ability, and/or an antidementia agent; a polypeptide, a polynucleotide, a vector, and a cell which may be used in the above screening; and a novel agent for improving the memory, a novel agent for improving learning ability, and/or a novel antidementia agent are disclosed. The above screening tool is composed of a calcium-permeable nonselective cation channel or a cell expressing the channel.

Method of screening agent for improving memory and learning ability

A novel polypeptide which is useful in searching for a therapeutic agent for diabetes, a polynucleotide encoding the polypeptide, an expression vector comprising the polynucleotide, a cell transfected with the expression vector, an antibody binding to the polypeptide, and a method of screening a therapeutic agent for diabetes are disclosed. The polypeptide is a novel background potassium channel expressed in the pancreas.

Potassium channel

There is provided a method of screening for substance that inhibits cell death induced by activation of PARP, particularly a substance that is useful as a therapeutic and/or preventive agent for rheumatoid arthritis, neuronal death at the time of cerebral ischemia, cell death of the heart after myocardial infarction reperfusion, autoimmune destruction of &#x3b2;-cells of pancreatic islets of Langerhans, cell death after shock, or inflammatory reaction by immunocyte death. Also provided are a novel protein and a novel gene encoding the same. The aforementioned screening method comprises a step of allowing a test substance to contact a cell expressing an LTRPC2 protein under a conditions such that the LTRPC2 protein can be activated, and a step of analyzing inhibition of LTRPC2 protein activation. The aforementioned novel protein is a rat or mouse LTRPC2 protein, and the aforementioned novel gene is a rat or mouse LTRPC2 gene.

Method of screening cell death inhibitor

Growing community of inventors

Tokyo, Japan

Kohei Inamura